Actual Coronavirus Testing Options Examined

Executive *******

*** ********* ***** ** entering **********, *** **** promising ****** ** ****** testing *** **** ** still ** ***********. *** most ****** **** (***/*********) is *** ********* *** too ****-********* ** ** applicable. ***** *** *** Antigen ***** ***** **** provide ****** ******** ******* in **-** ******* ***** be **** *** ********** testing *** ********* ** situations **** ***** *** waiting. ** ********, ******** tests ***** **** **** if ******* *** *** coronavirus *** ****** ******** it.

Asymptomatic *** ************** ******

****** ***** *******, *********** tests *** ******** ** detect ***** **** *** virus **** ** **** are ************ ** **************. People ***** **** ********** ** the *** **** ****** symptoms.*** ****** ********* **** ******* 80%** ****** **** **** cases ** *** ************. So, **** ********** ****** may *** **** ********. This ***** *********** ***** can ***** **** ********** individuals **** ***** ******* will ****.

Common *********/*** ****/***** ****/******* **** *************

*** **** ****** **** type ** *********/*** ***** which ********* ********, *********, ****, uncomfortable, *** ****** **** supply *********. **** *** ********* the **** ******** ****** for ********** *********** *** are *** ****** *** screening ** ******** *******. They *** ******* **** Amplification ** ******* *** amount ** *********** ** a ******, ****** **** more ********. ***, ************* causes *** ***** ** be *********, ********-*********, *** time-consuming. * *** ***** process * **** ** an ****, *** ******* need ** ** ***** to *** *** *** backlogs *****, ******* ******* to ***** **** **** after *******. **** *** also ************* ******* * nasal **** ***** ** be ******** **** **** the ****. ****,****-************ ******** *** ** ******** as ************** ************, ******* people ** *** *** the **** *** ****** up ***** *****. **** means ******** ******* ******** medical ************* *** ****** be *******-****. ** ** unclear *** **** ***** tests **** ** ************** carriers, *** **** *** currently *** **** ******** option.

*** *******,*** *** ** ***** daily *** ********* *** '******'.

Debate **** **** ** * ******** ******:

***** ** * ****** over **** ****** ***** as * ******** ***/******* Acid ************* *****. ***** tests ***’* **** * result ** ******** ** positive, *** *******, **** the ****** ** ************* cycles (**) ******** *** the ***** ** ** detected. ***** ******* **** more *****, *** * decrease ** ** ** 1 *********** ** * roughly ******** ** *** viral ****. **, * CT ** ** ***** someone *** ******* ***** the *********** **** ** a ** ** **. This **** ******* ***** that *** ******* **** amplification. **** ***** ***** any ***** ***** ** as * ******** ******, but**** ***** **** ** too****.* ****-******** ***** ********* **’* ***** ** was *** *** *** the ***** ** ********* in * ***, ********* that ***** ****** **** not **********. ***, ****** **** ***** ******** that******* ******* *********** ***** cutoffs ** **-** ** below **. **** ** significant, ******* * ******** of ******** ******* *** be **** *********** *** are ** ****** **********, who **** **’* ***** 30 ** **. ** means **** ********* *** being ****** ** ******* tracing *** ********* *** people *** *** ** longer **********.

Rapid *** *****

***** ***** *** ***** are ******* ** *********** PCR ***** *** ********* on * ******* *****, so ******* *** ******* and ***** ** **** for *********.

***** ***** ***** *** less ******** **** *********** PCR ******** * ******** ****** does *** *********** **** out ***********.** ******* (**-** *******), ***********, and *** ** **** with ******** *********. ***** are ***** * *** of ******** ***** ***** PCR ***** ******* **** are * ****** *********** and **** *** **** widely ****.

Saliva ***** ********* *****

****** ***** ********* ***** are ***** ******** ** an ***********, ****, ****** accurate ******** **** *** be **** *** *********.

**** ******* ****** ******* will ** **** ************ ***** ***** *****, but*** ***** *** ***** saliva **** ********. **** *** **** (1-15 *******) *** ***** cost **** **** $* making **** **** **********. They *** **** ******* on ******** *********, ***** could ******* ****** *********. Also, ****** ***** *** comfortable *** ******* *** easy *** ****** ** take **********. **** ***** that ** ******* ******* is ********, *** ****** professionals *** *** ****** for **********. ** **** means **** ****** *** dislike ***** ***** *** avoid ***** **** ******* them ***** *** ****** with ******-***** ********* *****.

***** **********,************ *** ********* ********* *** ************* by *** ***. ******** ********** ** *** testing** ***** ******, *********** ($1-$5), *** ****. ****, the ****'* ********** ***** ******** **** the ***. ******* *** ****** the ****, *** ********* the ******* **** *** PCR ***** **** ******* undertake, ** ***** ** verify *** ****'* ******** on ************ ********. ****** **** *********** $***,*** to *** ***** ******** and *** ****** ***** the ***.

Antigen *****

******* ***** *** **** accurate **** *********** *** molecular ***** *** **** established *** ***********, *** they *** ****** *** cheaper. **** **** *** proteins ********** **** *********** and ** *** ******* amplification. ***** *** ********* on * **** *****, much **** * ********* test, *********** *** **** for ********* ********* ** medical *************. ***** ******** results *** ********** ********, the*** ***** **** ******** results** *** *********** **** out ***********. ***, **** are ***** *** ***** be **** ********** **** molecular *****, **** **** tests *** ******** *** use *** ****** ****** are *********.***** ** ********* ******* tests **** ********* *** FDA **************** **** *** ******** developed, ** ********** ** still ***** ****** ** and ******** ** *******.

******:*** *.*. ********** *** purchased *** ************ ******* ***** ** increase *** *********** ******* capabilities ** *** ****** States. *** ************, ***** Labs, **** *** ***** take ** ******* ** run *** *** * shallow **** **** **** can ** ****-************. *** manufacturer ****** **% ********* with *** *****, *** it ** ******* ** that ** ***** ** self ** ************** ************ nose *****. ***** ***** are **** ******** ** individuals **** ******** *** Dr. ******* ********, ** infectious ******* ********* ** the ******* ********** ** South ********, **** *** NY ***** **** ** is ****** ** *** tests **** **** **** tested ** ************ ********:

** ***’* **** ******** about ***** *****’ ******** in ************ ********, ... We **** ** ** using ***** **** **** been ********* ** ***** performance.

*******, ******* **** ** not **** ** *************,**** *** **** **********-*********.

Benefits ** **** ******** ***** *******

*********** ***** ***** *** find ***** *********** *** testing ***** **** ******* traditional *** ***** *** too ****, ******-***********, *** cost-prohibitive *** ******** *******. They *** **** ** used *** *********, ***** could **** **** ********* facilities. ************** *** ************ individuals **** ** **** likely ** **** ***** tests, *** ***** *********** are *** **** ********* people ** ****. **** if **** *** **** accurate **** *********** *** tests, ***** ***** *** more ******** **** ** testing. *******, **** ** a **** ****** * case, * ******-** **** could ***** **. *********** PCR ***** *** *** inaccessible *** ******** *******, but **** ** ***** rapid ***** ***** ** taken ********** ** ****** populations. ****** *** ***** molecular, ******, ** ******* tests *** *** ***** may ** **** ******** than * ****** *********** molecular ****, *******, **** accessible, *** ***** **** a ********** ****** ** time. ****, *** ********** in ******** *** ** overstated ******* ** *** high ** ********* *** tests **** ******* **** Amplification ***. ******** *** results **** **-****** ********** individuals *** ** *********** counted ** ***** ********* for ***** *******, ******* of ***** ********* *** PCR *****.

Antibody *****

********/***** ***** ****** ***** someone *** *********** ** the ****,*** **** *** *** used ** ******** ****** cases. ******** ***** *** fast *** ********** ******** but **** ** *** work **** ***** *-* weeks ***** *********** ***********. In ********, ***** ** no *** ** *************** between ******* *** *** an ****** ********* *** someone *** *** ** active ********* ** *** past. **** ***** ******** tests *** *** *********** useful ** ***********. ******** tests *** * **** way *** ****** ****** officials ** ******** *** percent ** * ********** that *** *********** ** the ****, ******** ********* to ****** ****** ******* models.

** ** ********* ** remember **** * ******** result *** ******** ** active *********, ** ****** should *** ***** * positive ****** ** ********. Do *** *** **** you ****** ****** ***********, just ******* *** **** a ******** ******** ****.

How *** * *** ******?

**** ******* ** ***** you ****, *** **** likely ******* **** ********** provider *** *** ****** be **** ** ******* options ******* **** ***** healthcare ******. ***** *** largely ***** *********** ********** in ******* ******* ** through ******* ******* ***** they ***** ******* *************. In ********,* ************ ******* **-**** ***** that *** **** **** for * ****** ** the *.*. **** **** between $***-$*** ********* ** ***** ******* by ************** *** ***** ***. Currently, **** *********** *** and ******** ***** *** widely ********* ******, *** traditional *** ***** *** less ******** **** *** swab ** ****-************. *******, there ** * *** of ***** *********** ***********, and**** ***** *** ***** sold** ** ** ********* to ****** **** **** is ********** ** *********** authorities.

Corporate *********

** ** ******** *** large ************ ** ****** relationships **** **** (** their *** ***) *** at ***** *** ******* is ********* ***** ** smaller ************.***** ******** *** ************* *** **** ****** and ***** ****, ** ensure ***** ********* *** get ******, ********* ** ******** *** own***, *** *** ******* companies, ***** *** ***** options. ** *** **,********* ********* ******* *********** solutions ********* *** *** antibody *****. *******'* ******** will ****** **** **** than ********** ***** ******* of ****, *** **** still ** ********** *********, take ******* **** ** process, *** ** **** at ****, ******** *** suffer *** ** ******** sample **********.

Future ** *******, ***** ***** *********, *** ********* ****** *****

******* ********* *** ******** new ******* *** ********* tests **** ***** ****** the ********* *********.**** ***** ******* *** rapid ************** *** ***** ****** and ***** **** ** widely *********. ** ********, at ******** *****-**** ********* * ******-***** kiosk. **** ***** ******** results ***** ** ******* but *** ******* ** decrease ********** ****. *********** would **** * ****** sample, **** * ***** amount ** ****, *** receive * ****** ******** diagnosis. **** ***** ** valuable *** ********* ******* areas ** **********. ******** the ***** **** ****** be **** ******** **** traditional *** *****, ** will ** **** **** accurate **** ***** ********* for *********** *********. **** being ****, *** ******* landscape ** ***** *** deception *** ** ** important** *** ******* ***** the ****** ** ******* startups.

More ***********

**** ** ******** ** a ******* ************. *** more ********* / ******* data, **** ** ********** for ********** *** *********** (****) * *** ************* non-profit **** ** ******** Coronavirus ***** *** ********* their ********. ****, *** accuracy ** ********* **** real-life ********, ***** ******** complicated **********.**** *** ******* ******* of ******** *************** ******** ** ******* and *** * ***** that *** **** *** interpret **** * ******** test ****** ***** ***** on *** ****'* ******** and **** ********** ** being ********.

Outlook / ******

*** ********* ** ******* reports ** **** ******** in ***** *** *** saliva *** ******** ***** in ****. *** *** or ****** **** ******* is, ** ******, ******* now. *******, ** **** to ******** ** ***** these ************ ** ******* better *********** ** ********** look ** ******* ********, from ***** ******* ** spit *****, ** ****** secure ***** *************.